Zhen-Bin Ding

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/772274/publications.pdf

Version: 2024-02-01

42	2,541	279798	265206
papers	citations	23 h-index	42 g-index

42	42	42	6609
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy, 2011, 7, 1159-1172.	9.1	287
2	Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 9167-9175.	0.9	245
3	Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy, 2013, 9, 2056-2068.	9.1	222
4	Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. International Journal of Oncology, 2015, 46, 587-596.	3.3	177
5	Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation. Clinical Cancer Research, 2011, 17, 6229-6238.	7.0	162
6	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer, 2018, 18, 1148.	2.6	113
7	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. Gastroenterology, 2014, 146, 1397-1407.	1.3	111
8	Cell Culture System for Analysis of Genetic Heterogeneity WithinÂHepatocellular Carcinomas and Response to Pharmacologic Agents. Gastroenterology, 2017, 152, 232-242.e4.	1.3	107
9	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology, 2019, 69, 143-159.	7.3	105
10	Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut, 2021, 70, 951-961.	12.1	93
11	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. Cancer Cell International, 2019, 19, 71.	4.1	92
12	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6, 846-861.	1.8	84
13	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. Cancer Letters, 2018, 412, 108-117.	7.2	79
14	Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. Journal of Hepatology, 2018, 69, 89-98.	3.7	63
15	Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptorâ€“induced epithelialâ€mesenchymal transition. Hepatology, 2015, 62, 1201-1214.	7.3	49
16	Liverâ€intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virusâ€positive hepatocellular carcinoma. Cancer, 2009, 115, 4753-4765.	4.1	46
17	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics, 2018, 8, 5690-5702.	10.0	45
18	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. International Journal of Oncology, 2016, 49, 2367-2376.	3.3	39

#	Article	IF	Citations
19	Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget, 2016, 7, 2867-2877.	1.8	38
20	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget, 2017, 8, 5135-5148.	1.8	35
21	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 169-178.	1.5	32
22	FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-Î²/Smad2/3 signaling pathway. BMC Cancer, 2017, 17, 648.	2.6	32
23	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Medicine, 2019, 17, 106.	5.5	31
24	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer, 2019, 10, 5575-5584.	2.5	28
25	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Annals of Translational Medicine, 2020, 8, 487-487.	1.7	25
26	Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma. Journal of Pathology, 2017, 243, 407-417.	4.5	22
27	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. Molecular Oncology, 2022, 16, 549-561.	4.6	21
28	SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. Acta Pharmacologica Sinica, 2018, 39, 243-250.	6.1	16
29	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer, 2018, 9, 1106-1112.	2.5	16
30	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. Journal of Cancer, 2018, 9, 1025-1032.	2.5	14
31	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell International, 2022, 22, 128.	4.1	14
32	Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 910-920.	2.4	13
33	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. BMC Cancer, 2017, 17, 762.	2.6	12
34	Autophagy activation contributes to glutathione transferase Mu 1â€‘mediated chemoresistance in hepatocellular carcinoma. Oncology Letters, 2018, 16, 346-352.	1.8	12
35	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunology, Immunotherapy, 2019, 68, 1369-1378.	4.2	12
36	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. British Journal of Cancer, 2020, 123, 92-100.	6.4	10

#	Article	IF	Citations
37	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer, 2020, 20, 642.	2.6	9
38	Laparoscopic vs. Open Repeat Hepatectomy for Recurrent Liver Tumors: A Propensity Scoreâ€“Matched Study and Meta-Analysis. Frontiers in Oncology, 2021, 11, 646737.	2.8	9
39	Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). Cancer Research, 2021, 81, 486-486.	0.9	7
40	Laparoscopic Versus Open Left Lateral Segmentectomy for Large Hepatocellular Carcinoma: A Propensity Scoreâ€“Matched Analysis. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 513-519.	0.8	6
41	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging, 2019, 11, 11111-11123.	3.1	6
42	Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. Infectious Agents and Cancer, 2017, 12, 28.	2.6	2